Shifting the Paradigm in Small Cell Lung Cancer: Targeting Tumor Biology to Transform Patient Outcomes

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Charles M. Rudin, MD, PhD; Alex A. Adjei, MD, PhD; and Millie Das, MD; discuss the latest treatment advances for extensive-stage small cell lung cancer (ES-SCLC), including how to sequence bispecific T-cell engagers and antibody-drug conjugates and ways to manage adverse events associated with these newer therapies.

To learn more about this topic, including information on the latest treatment advances in limited-stage SCLC and prophylactic cranial irradiation, go to https://www.gotoper.com/stp26sclc-activity.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Incorporate proactive strategies to monitor and mitigate treatment-related toxicities in patients with SCLC
• Evaluate emerging therapeutic strategies and consider potential implications in the context of evolving paradigms across the SCLC treatment continuum

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc; Merck Sharp & Dohme, LLC; and Jazz Pharmaceuticals, Inc.

PER is proud to partner with the LUNGevity Foundation.

Faculty:

Charles M. Rudin, MD, PhD

Deputy Director
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Adviser, Consultant, Fee-for-Service Recipient:Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Merck, Roche; Grant/Research Funding: Amgen, Daiichi Sankyo, Merck; Royalty or Patent Benefits: Licensing and royalty payments related to DLL3 therapeutics

Alex A. Adjei, MD, PhD

Chief, Cancer Institute
Cleveland Clinic
Cleveland, OH

Disclosures: Alex A. Adjei, MD, PhD, has no relevant financial relationships with ineligible companies.

Millie Das, MD

Clinical Professor, Medicine - Oncology
Chief, Oncology
VA Palo Alto Health Care System
Stanford Cancer Institute
Palo Alto, CA

Disclosures: Adviser, Consultant, Fee-for-Service Recipient: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, EMD Serono, Genentech, Gilead, Janssen, Jazz, Lilly, Merus, Natera, Novartis, OncoHost, RayzeBio, Regeneron, Summitt; Grant/Research Funding: CellSight, Genentech, Merck, Varian; Executive Role: President of ANCO (Association of Northern CA Oncologists)

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Release Date

April 9, 2026

Expiration Date

April 9, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.